Literature DB >> 28070627

[Tendinopathy in rheumatic diseases].

M Henniger1, S Rehart2.   

Abstract

Involvement of tendons and tendon sheaths is frequently found in the most common inflammatory systemic diseases, rheumatoid arthritis and spondyloarthritis. In rheumatoid arthritis tendon manifestations occur as tenosynovitis, with swelling and pain of the tendons mainly on the hands and feet. In spondyloarthritis the involvement of tendons presents as enthesitis with pain and swelling directly at the attachment points of tendons to the bony structures and more commonly in the lower extremities. Pathological alterations of tendons can be normally visualized by sonography and only sometimes with magnetic resonance imaging (MRI) or scintigraphy. Furthermore, it is important for diagnostics and effective therapy to detect all joints involved by means of clinical, sonographic and radiological examination as well as laboratory parameters of inflammation, antibody serology (e.g. anti-CCP antibodies) and HLA-B27. The histopathological alterations of tendinopathy in rheumatic diseases differ from degenerative/posttraumatic tendinopathy in their expression of the changes; however, a clear differentiation of the different rheumatic inflammatory systemic diseases is histopathologically not possible. Therapeutically, systemic medication is the most important part of treatment in rheumatic diseases. Local therapeutic measures can be employed in the treatment of tenosynovitis and enthesitis. In the case of failure or lack of efficacy of the medication and conservative therapy, tenosynovectomy is performed for persistent tenosynovitis and reconstructive surgical procedures are necessary for tendon ruptures.

Entities:  

Keywords:  Enthesitis; Psoriatic arthritis; Rheumatoid arthritis; Spondyloarthritis; Tenosynovitis

Mesh:

Substances:

Year:  2017        PMID: 28070627     DOI: 10.1007/s00113-016-0291-0

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  19 in total

Review 1.  Enthesitis, osteitis, microbes, biomechanics, and immune reactivity in ankylosing spondylitis.

Authors:  D McGonagle; P Emery
Journal:  J Rheumatol       Date:  2000-10       Impact factor: 4.666

2.  Synovitis score: discrimination between chronic low-grade and high-grade synovitis.

Authors:  V Krenn; L Morawietz; G-R Burmester; R W Kinne; U Mueller-Ladner; B Muller; T Haupl
Journal:  Histopathology       Date:  2006-10       Impact factor: 5.087

3.  [Synovialitis score: histopathological grading system for chronic rheumatic and non-rheumatic synovialitis].

Authors:  V Krenn; L Morawietz; G-R Burmester; T Häupl
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

4.  Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.

Authors:  Cong-hua Wang; Yuan Feng; Zhen Ren; Xichao Yang; Jun-feng Jia; Meng-yao Rong; Xue-yi Li; Zhen-biao Wu
Journal:  Clin Rheumatol       Date:  2015-04-21       Impact factor: 2.980

5.  Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.

Authors:  J Braun; M Bollow; G Remlinger; U Eggens; M Rudwaleit; A Distler; J Sieper
Journal:  Arthritis Rheum       Date:  1998-01

6.  Six months open label trial of leflunomide in active ankylosing spondylitis.

Authors:  H Haibel; M Rudwaleit; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

7.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

8.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

9.  [Differential diagnosis of synovitis].

Authors:  L Morawietz; G Fernahl; V Krenn
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 10.  Treatment recommendations for psoriatic arthritis.

Authors:  C T Ritchlin; A Kavanaugh; D D Gladman; P J Mease; P Helliwell; W-H Boehncke; K de Vlam; D Fiorentino; O Fitzgerald; A B Gottlieb; N J McHugh; P Nash; A A Qureshi; E R Soriano; W J Taylor
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

View more
  1 in total

1.  Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model.

Authors:  Frideriki Poutoglidou; Chryssa Pourzitaki; Maria Eleni Manthou; Efthimios Samoladas; Athanasios Saitis; Foteini Malliou; Dimitrios Kouvelas
Journal:  Inflammopharmacology       Date:  2021-05-12       Impact factor: 4.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.